Omada, the virtual chronic care provider, joins virtual physical therapy company Hinge Health in testing the public market’s ...

The Trump administration laid out for the first time how Part B drugs could be selected for Medicare drug price negotiations ...

A handful of generic and biosimilar manufacturers have said they feel prepared to ride out President Donald Trump’s potential ...

White House drug pricing plan faces skepticism as experts question feasibility of Trump's executive order to align US prices ...

GSK said it is axing development of belrestotug and concluding its iTeos collaboration, which began with $625 million upfront ...

To­day on Post Hoc Live, Drew Arm­strong is joined by Nick Ship­ley, the for­mer top lob­by­ist for the biotech in­dus­try, ...

Galapagos is turning heads by reconsidering whether to do its planned spinoff, which was originally announced in January.

Bayer cuts 2,000 jobs in Q1 2025, reaching 11,000 total layoffs amid reorganization. CEO Bill Anderson reports strong pharma ...

Azafaros raises $146M Series B to advance nizubaglustat into Phase 3 trials for rare lysosomal storage disorders, with ...

Vir Biotech's hepatitis B therapy shows 4% cure rate with doublet (tobevibart/elebsiran) and 10% with triplet therapy, below ...

House tax bill includes PBM reforms, spread pricing restrictions & orphan drug negotiation changes, with Rep. Guthrie leading ...

Roche said its $50 billion promise to expand its manufacturing footprint in the US has the potential to be 'reassessed.' ...